Chikungunya Club Meeting (7.24.2026) Dr. Jack Cush reviews the news, journal reports from the past week on RheumNow. Take this week's RheumIQ quiz to test your knowledge! https://t.co/UNoKMdclnj https://t.co/XpGfx1fJLu

Swimming Reduces Disability from Low Back Pain Swimming is commonly recommended for patients with chronic low back pain. Yet, there is little trial data investigating swimming. An Australian study has shown for the first time that a program of swimming can be clinically https://t.co/OfxsvRjyJg

Evidence-Based Dietary Recommendations for Gout Gout, historically referred to as the “disease of kings,” was once associated with a lifestyle of excess. Today, it is more appropriate to refer to gout as a “disease of commoners,” as it is the most common inflammatory arthritis https://t.co/uIrSeOjxJZ

3 Rx are FDA approved for hidradenitis supprativa (secukinumab, adalimumab, bimekizumab). New JAK1i Povorcitinib in STOP-HS1 and STOP-HS2 ph 3 PCTs (608/619 pts). Povo showed HiSCR50 ~42% vs PBO 29% @wk12. AE: acne, pharyngitis https://t.co/n3FJUOjNuo https://t.co/9YAmPqW44z

Interferon-α as an Immunologic Driver of Sjögren's Disease Using data from a Sjogren's registry, researchers have shown that IFNα drives Sjögren's disease, and can be elevated a decade before diagnosis. This study assessed the role of type 1 interferon (IFNα) in its onset and https://t.co/0BDDvR5cUB

Persistence of education and monitoring is crucial to optimal gout management Optimal gout care is dependent on having a well-informed health care provider who recognizes and follows the ACR gout management recommendations. It is important that the misconceptions and myths held https://t.co/wDvgwUg2P1

Pragmatism in Gout: How therapeutic choices can have multiple benefits Drugs prescribed to calm flares or lower uric acid are designed with one primary goal in mind, yet many also produce meaningful effects beyond the joints. Some of those secondary effects are unwelcome; such https://t.co/QvXAwFM7LJ

Future therapies (in development) for gout - the goal is durable crystal depletion. Created by: Dr. Aravind Palraj @rheumat_aravind for RheumNow. https://t.co/rzP8usVZnT https://t.co/ZDuVWqT2TA

Psoriasis = Myocardial Dysfunction (unrelated to Cardiometabolic Risk Factors) 1010 PsO pts vs controls w/o skin dz, assessed clinically & by ECHO. PSO pts (even w/ controlled dz) had signif more myocardial dysfunction (17% vs 6%). Higher BMI & DM independently assoc w/ https://t.co/MjcRmgyCWX

STOP-HZ trial - 30 #RA pts going on tofacitinib given Shingrix (RZV) on day 1 & wk 8 & started Tofa on d1 or wk8. @wk 12 VZV responses incr in both (2.66 & 2.91 fold incr). @wk 4, d1 Tofa had fewer ≥1.5-fold VZV vs wk8 (44.8% vs 80%); BUT can you wait 8wks to start JAKi? https://t.co/tH0zPgBbHQ